These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4840450)

  • 1. Disk susceptibility studies with cefazolin and cephalothin.
    Actor P; Guarini J; Uri J; Dickson J; Pauls JF; Weisbach JA
    Antimicrob Agents Chemother; 1974 Jan; 5(1):63-7. PubMed ID: 4840450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro comparison of cefazolin with other cephalosporins.
    Yeivin R; Meshulam M; Sacks T
    Isr J Med Sci; 1974 Sep; 10(9):1092-5. PubMed ID: 4436031
    [No Abstract]   [Full Text] [Related]  

  • 3. [Susceptibility to first-generation Cephalosporins in Enterobacteriaceae isolated from urine culture according to CLSI and EUCAST breakpoints].
    Corvalán V; Hervé B; Sanhueza C; Martínez N; Almonacid M; Fuente S
    Rev Chilena Infectol; 2018; 35(3):329-331. PubMed ID: 30534916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability of cefaclor, cefazolin, cefamandole, and cephalothin disks to predict susceptibility of Enterobacteriaceae, Staphylococcus species, and Haemophilus influenzae.
    Barry AL; Jones RN; Thornsberry C
    Am J Clin Pathol; 1985 Nov; 84(5):643-8. PubMed ID: 3877452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cefazolin against recent clinical bacterial isolates.
    Sabath LD; Wilcox C; Garner C; Finland M
    J Infect Dis; 1973 Oct; 128():Suppl:S320-6. PubMed ID: 4200651
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of cefazolin, a new cephalosporin antibiotic.
    Reller LB; Karney WW; Beaty HN; Holmes KK; Turck M
    Antimicrob Agents Chemother; 1973 Apr; 3(4):488-97. PubMed ID: 4790605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of in vitro antimicrobial activity of cefamandole and cefazolin with cephalothin against over 8,000 clinical bacterial isolates.
    Jones RN; Fuchs PC
    Antimicrob Agents Chemother; 1976 Jun; 9(6):1066-9. PubMed ID: 938021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of clinical isolates of Enterobacteriaceae to BL-S640, a new oral cephalosporin.
    Watanakunakorn C; Bannister T; Glotzbecker C
    Antimicrob Agents Chemother; 1975 Mar; 7(3):381-5. PubMed ID: 1137392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inability of cephalothin testing to predict cefprozil susceptibility.
    Fung-Tomc J; Stickle T; Doyle C; Huczko E; Kessler RE
    J Clin Microbiol; 1991 Nov; 29(11):2643-7. PubMed ID: 1774280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cephalothin and cefazolin in vitro antibacterial activity and pharmacokinetics in dogs.
    Petersen SW; Rosin E
    Vet Surg; 1995; 24(4):347-51. PubMed ID: 7571387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistance Staphylococcus epidermidis.
    Siebert WT; Moreland N; Williams TW
    J Infect Dis; 1979 Apr; 139(4):452-7. PubMed ID: 438546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cephalothin is not a reliable surrogate marker for oral cephalosporins in susceptibility testing of Enterobacteriaceae causing urinary tract infection.
    López IA; Montes JC; Álvarez MJ; Mazarrasa CF; Martínez-Martínez L
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):412-416. PubMed ID: 27640080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between in vitro susceptibility and efficacy in experimental mouse infection-protection assay of cefazolin and cephalothin using Escherichia coli strains.
    Uri JV; Actor P; Phillips L; Guarini JR; Weisbach JA
    Chemotherapy; 1976; 22(5):313-8. PubMed ID: 780071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiological activity of cefazedone as compared to cefazolin and cephalothin.
    Knothe H
    Arzneimittelforschung; 1979; 29(2a):378-81. PubMed ID: 39575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Another look at differences in the susceptibility of Escherichia coli and Klebsiella pneumoniae to cephalothin and cefazolin.
    Yeh LL; Chi CL
    Int J Antimicrob Agents; 2001 Jun; 17(6):521-4. PubMed ID: 11397625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal activity and pharmacology of cefazolin.
    Bergeron MG; Brusch JL; Barza M; Weinstein L
    Antimicrob Agents Chemother; 1973 Oct; 4(4):396-401. PubMed ID: 4598612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antibacterial activities of cephalosporin antibiotics: cefazolin, cephaloridine, cephalothin, and cephalexin.
    Hsieh WC; Ho SW
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1975 Mar; 8(1):1-11. PubMed ID: 1097210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro studies with cefazolin.
    Motley M; Shadomy S
    Antimicrob Agents Chemother; 1974 Dec; 6(6):856-61. PubMed ID: 4451358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new parenteral cephalosporin. SK&F 59962: in vitro and in vivo antibacterial activity and serum levels in experimental animals.
    Actor P; Uri JV; Guarini JR; Zajac I; Phillips L; Sachs CS; DeMarinis RM; Hoover JR; Weisbach JA
    J Antibiot (Tokyo); 1975 Jun; 28(6):471-6. PubMed ID: 238925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of BL-s640 against gram-negative bacilli and Staphylococcus aureus compared with activity of four other semisynthetic cephalosporins.
    Vuye A; Pijck J; Soep H
    Antimicrob Agents Chemother; 1976 Mar; 9(3):422-32. PubMed ID: 1259401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.